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Summary 
Burning mouth syndrome (BMS) is a chronic orofacial pain disorder of unknown 
cause. It is more common in peri- and postmenopausal women, and sex hormone 
dysregulation is believed to be an important causative factor. Psychosocial events 
often trigger or exacerbate symptoms, and persons with BMS appear to be 
predisposed toward anxiety and depression. Atrophy of small nerve fibers in the 
tongue epithelium has been reported, and potential neuropathic mechanisms for BMS 
are now widely investigated. Historically, BMS was thought to comprise 
endocrinological, psychosocial, and neuropathic components. Neuroprotective 
steroids and glial cell line–derived neurotrophic factor family ligands may have pivotal 
roles in the peripheral mechanisms associated with atrophy of small nerve fibers. 
Denervation of chorda tympani nerve fibers that innervate fungiform buds leads to 
alternative trigeminal innervation, which results in dysgeusia and burning pain when 
eating hot foods. With regard to the central mechanism of BMS, depletion of 
neuroprotective steroids alters the brain network related mood and pain modulation. 
Peripheral mechanistic studies support the use of topical clonazepam and capsaicin 
for the management of BMS, and some evidence supports the use of cognitive 
behavioral therapy. Hormone replacement therapy may address the causes of BMS, 
although adverse effects prevent its use as a first-line treatment. Selective serotonin 
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reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors 
(SNRIs) may have important benefits, and well-designed controlled studies are 
expected. Other treatment options to be investigated include brain stimulation and 
TSPO (translocator protein 18 KDa) ligands. 
 
Introduction 
Burning mouth symptoms that occurred as secondary phenomena attributable to 
local conditions1–9 were previously referred to as “secondary” burning mouth 
syndrome (BMS),10 but BMS now refers only to burning symptoms not attributable to 
local or systemic causes.11 After excluding such conditions, some common 
characteristics of BMS are important. Burning sensations are usually bilateral, and 
intensity fluctuates.2 The most common site is the tip of the tongue, but pain is often 
noted at the lateral border of the tongue, lips, and hard palate.12 Affected persons 
often complain of dysgeusia,13 which may be accompanied by subjective 
xerostomia.14 Peri- and postmenopausal women are predisposed to the condition. 
Some patients exhibit depressive symptoms and anxiety15–18 and may express 
concern regarding the presence of a malignant condition.10,16 Psychosocial stressors 
can trigger or worsen pain,15,19 while eating and drinking usually alleviate pain.10,20 
These manifestations are characteristic features of BMS and should not be excluded 
as secondary signs or symptoms of primary disease. Agreement on these clinical 
features yields important clues in understanding the underlying pathophysiology of 
BMS.  
Despite considerable knowledge regarding these common manifestations, 
BMS remains an idiopathic orofacial pain condition and one of the most frequently 
studied oral pathologies in pain research. Although a neuropathic etiology is 
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suspected by some researchers,21 traditional chronic pain classifications do not 
include BMS in the neuropathic pain group.22,23 This review surveys the literature 
regarding the pathophysiology of BMS and examines the condition from neuropathic, 
endocrinological and psychological perspectives. 
 
1. Etiological perspectives 
Although BMS remains an idiopathic pain condition, some findings are frequently 
observed in BMS patients. BMS has long been thought to be associated with 
psychosocial distress and to be induced by mental disorders like depression and 
anxiety.17,24 The higher incidence of BMS in postmenopausal women led to a 
diagnosis of climacteric disorder.25–27 This consensus increased the research focus 
on psychological stress, and many studies attempted to identify relationships 
between psychosocial,28,29 endocrinological,30,31 and immunological32,33 factors 
believed to be associated with mental stress. Nevertheless, the cause of BMS 
remained elusive. In the late 1980s, studies began to report neurophysiological and 
electrophysiological data of BMS patients and yielded new important neurological 
insights.34–36 Numerous pathological and imaging studies followed and led to the 
hypothesis that BMS could be a neuropathic pain condition.37–39 Accumulating 
evidence suggests that the cause of BMS involves psychosocial, endocrinological, 
and neuropathic components.37–40 Studies have examined its etiology and 
pathophysiology by analyzing clinical data or by using animal models that mimic 
characteristic findings. To clarify the signs and symptoms of BMS, this review will 
examine these three pathophysiological components and their possible relationships.  
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1) Neuropathic component 
In 2005, Lauria et al. observed that small nerve fibers in the tongue epithelium were 
atrophied in BMS patients.37 They also found a decrease in the number of nerve 
fibers innervating taste buds. These observations suggested that BMS patients could 
have peripheral neuropathy. Peripheral nerve atrophy specifically occurred in 
small-diameter fibers in the epithelium of BMS patients; subepithelial nerve fibers 
were less often affected.40,41  
BMS patients frequently complain of dysgeusia and phantom taste.42–44 
Dysgeusia is defined as persistent alteration of taste in the presence of taste 
stimulation. Phantom taste is defined as an abnormal taste occurring in the absence 
of stimulation.45 Studies reported that the ratio of taste detection threshold and 
tingling sensation was significantly altered in BMS patients46 and that this alteration 
depended on the duration of symptoms.47 These abnormal taste sensations are 
common symptoms of BMS and are believed to be involved in the etiology of BMS. 
The most common phantom tastes reported in BMS patients are “bitter” and “metallic” 
tastes.48,49 Phantom taste likely results from disinhibition of the glossopharyngeal 
nerve after damage to the chorda tympani nerve.47,48 The morphological studies 
discussed above reported decreases in the density of myelinated and unmyelinated 
thin fibers in the tongue epithelium of BMS patients.37,40,50 These small-diameter 
fibers, which are normally observed in taste buds and receive impulses from taste 
cells, are absent in the taste buds of BMS patients; only fibers very close to taste 
buds surrounding papillae remain.51 Grushka et al. reported that the density of 
fungiform papillae was greater in BMS patients than in controls and suggested that 
this high density of fungiform papillae could be a risk factor of BMS.52 These findings 
are of concern, as they suggest that dysgeusia/phantom taste may be a kind of 
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neuropathic symptom caused by deafferentation of the chorda tympani nerve.47,48 
The challenge then remain to explain the trigger or cause of such a deafferentation in 
the absence of macro-trauma to the nerve. 
Studies of the interaction of pain and taste have yielded a number of 
important insights. First, trigeminal and gustatory nerve fibers may interact by a 
peripheral mechanism. The anterior two thirds of the tongue is innervated by chorda 
tympani nerve fibers of the lingual nerve. This is the area most commonly affected by 
BMS, and it has a large number of taste buds in fungiform papillae.53,54 These 
papillae and taste buds innervated by chorda tympani nerve fibers survive even after 
denervation of the chorda tympani nerve.55 When this occurs, substance P (sP) and 
calcitonin gene–related peptide (CGRP)–containing nerve fibers are important in 
nerve fiber survival.56 After chorda tympani nerve injury in the middle ear, surviving 
taste buds in fungiform papillae in the territory of the chorda tympani nerve 
disappeared after application of capsaicin, which depletes sP and CGRP.56 
Furthermore, fungiform papillae are innervated by fibers expressing P2X2 and P2X3 
receptors and those expressing transient receptor potential vanilloid 1 (TRPV1). Most 
P2X2 and P2X3 immunoreactivity was abolished after transection of the chorda 
tympani nerve, although TRPV1 immunoreactivity remained unchanged.57 These 
findings indicate that most fungiform papillae nerve fibers expressing P2X2 and P2X3 
receptors are derived from the chorda tympani nerve, whereas 
TRPV1-immunoreactive fibers derive from the trigeminal nerve.57 These findings in 
animals suggest that purinergic fibers are involved in conducting taste signals and 
that TRPV1-positive fibers that conduct hot “taste” and nociceptive signals take over 
after denervation of these purinergic fibers. Previous studies reported increased 
expression of TRPV1,40 nerve growth factor (NGF),40 and P2X receptors41 in 
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damaged small nerve fibers from BMS patients. Further, changes were noted in the 
expression of endocannabinoid receptors cannabinoid (CB)1 and CB2, which 
modulate TRPV1 activation.58 CB2 but not CB1 is important in anti-nociception in the 
trigeminal system.59 In BMS patients, CB1 is suppressed, while TRPV1 and CB2 
expression is high.58 Taken together, these findings suggest an accelerated role of 
TRPV1 receptors in BMS. Patients often complain of hypersensitivity to capsaicin but 
not to taste stimuli. Capsaicin causes a bitter taste, and some salts, like CuSO4, 
ZnSO4, and FeSO4, mediate metallic taste via TRPV1.
60 These findings could 
possibly explain the peripheral mechanism of pain–taste interaction. Thus, in 
summary denervation of the chorda tympani nerve fibers that innervate fungiform 
buds may lead to alternative trigeminal innervation, which subsequently could result 
in dysgeusia and pain when eating hot food.  
Second, central involvement was reported in the pain–taste interaction. There 
are two pathways that conduct nociceptive signals to the brain stem through 
trigeminal afferents. First, trigeminal afferents travel along the trigeminal spinal tract 
and reach the trigeminal spinal nuclei, and second, a certain portion of trigeminal 
afferents reach the nucleus tractus solitarii (NTS) directly. 53,54,61 Trigeminal afferents 
have interconnections with chorda tympani nerve fibers at both sites. Although chorda 
tympani nerve fibers reach the NTS and connect with trigeminal sensory subnuclei 
via interneurons,53,62 it is reported that subnucleus caudalis neurons receiving 
nociceptive thermal inputs do not receive any gustatory controls.63 Contrarily, 
evidence indicates that the chorda tympani, glossopharyngeal, and trigeminal nerves 
control their functions mutually and that impulses from these nerve fibers help 
modulate interrelated nerve activity in the NTS.53,54,64 Morphological studies have 
revealed that there are many NTS neurons projecting to the parabrachial nucleus 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
(PBN) and few neurons projecting to the thalamus.61,65 Further, ascending projections 
from the PBN terminate in the central amygdaloid nucleus and thus nociceptive 
information from the NTS is mainly transmitted to the medial pain system, but not to 
the lateral pain system.61,66 BMS patients report that pain is alleviated by eating 
non-hot food and drinking.20 Hirsch reported that topical sucralose alleviated pain in 
BMS.67 Schöbel reported a sweet taste and chorda tympani nerve block alter 
capsaicin-induced lingual pain in adults and that oral capsaicin suppressed central 
taste transmission.68 Dental deafferentation may also lead to a taste deficit.69 Lehman 
et al. studied the effect of nerve blocks on gustatory function70 and found diminished 
taste sensation in bilateral glossopharyngeal nerve territory after a lingual nerve block. 
However, the taste sensitivity of the left (contralateral) glossopharyngeal nerve 
increased after right chorda tympani nerve block.70 Further, they reported evidence of 
an obvious acceleration in contralateral taste sensation not only in the chorda 
tympani nerve but also in the glossopharyngeal nerve territory after unilateral chorda 
tympani nerve block.45 This acceleration was also observed in the bilateral 
glossopharyngeal nerve territory after bilateral chorda tympani nerve block.45 These 
local anesthetic studies of the lingual and chorda tympani nerves suggest the 
possibility of central modulation rather than peripheral interaction of these nerves.45,70 
A functional MRI (fMRI) study showed evidence of inhibition of brain activation in 
pain-related regions during a cold pressor test after administration of glucose71. 
These results suggest that taste impairment disinhibits taste analgesia. Damage to 
the chorda tympani nerve may block its inhibitory action on the trigeminal nerve and 
disinhibitory action on the glossopharyngeal nerve, which are seen not only at the 
medullary level but probably at higher levels, as well. Taken together, the evidence 
indicates that small fibers in the tongue epithelium atrophy in BMS and that impulses 
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from these afferents decrease. Under such conditions, mutual sensory modulation by 
these nerves changes at the NTS. Further, deafferentation–hyperactivity of the 
somatosensory regions of the trigeminal system might develop after loss of pain 
inhibition, due to taste fiber damage of the chorda tympani nerve.20,46,72,73 
BMS patients often complain of pain when eating hot or spicy foods.74 
Quantitative sensory testing (QST) studies of the pain threshold of BMS patients have 
yielded inconsistent findings. Some studies observed increased sensitivity in warm 
and cold detection,75 increased thermal pain sensitivity (warm76 and cold75 allodynia), 
and heat hyperalgesia,34,77 while others reported less sensitive changes in warm36,78 
and cold78,79 detection in the affected area in BMS patients. While changes in pain 
and detection thresholds to warm and cold stimuli have been inconsistent, BMS 
patients clearly have decreased pain tolerance to noxious heat stimulation34,77 and 
topical capsaicin.36,75 Ito reported prolonged pain perception not only to painful heat 
but to cold and mechanical stimulation, as well.77 Our study revealed accumulated 
pain response was increased, although pain threshold was not decreased in BMS 
patients.80 These findings suggest that once persons with BMS perceive pain, 
tolerability is reduced.34 An electrophysiological study reported that habituation of the 
blink reflex can be suppressed in 20–36% of BMS patients.35 These psychophysical 
and electrophysiological studies revealed abnormal responses that suggest temporal 
summation induced by central sensitization. Electrophysiological data revealed an 
exaggerated response in the trigeminofacial systems and trigeminal brainstem 
complex in patients with primary BMS.81 BMS patients had an abnormal 
pain/detection threshold ratio in the extraterritorial region of the trigeminal system.36 
Local anesthetic block relieved pain in some BMS patients;82 however, 
somatosensory blockade of trigeminal inputs aggravated pain in some patients.82,83 
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Gremeau-Richard observed comorbid mental distress in patients for whom lingual 
nerve block and topical clonazepam were ineffective.82 These findings cannot be 
explained only by a peripheral mechanism. 
 
2) Endocrinological component 
What causes deafferentation of thin nerve fibers? In 2009, Woda et al.27 proposed 
that reduced synthesis of ovarian steroids after menopause induces deficiency or 
dysfunction in adrenal steroids, which abolishes the neuroprotective effects of 
steroids on neural tissues.27 Because BMS is an idiopathic condition, there are no 
animal models that clearly explain how depletion of gonadal steroids might result in 
morphological changes in somatosensory and gustatory fibers in the tongue. 
However, researchers have used animal models that mimic some major symptoms of 
BMS to study its pathophysiology. Ovariectomized animals are often used.84 One 
study reported that the number of vaginal nerve fibers decreased after ovariectomy.84 
Ovariectomy induces thinning of tongue epithelium,85,86 especially the keratinized 
layer,86 and BMS patients also exhibit specific changes in the keratinized layer. In 
BMS patients, keratin 16, which is present in hyperproliferative epithelial cells, is 
abundant in spinous keratinocytes, which means keratinocytes are activated after 
possible epithelial damage.87 Ovariectomy leads to upregulation of glial cell 
line–derived neurotrophic factor (GDNF) family ligands and their receptors.88 mRNA 
expression of the GDNF family member artemin was increased in epithelial cells 
scraped from the tongues of BMS patients.89 Animal models associated with 
increased artemin expression showed a fluorescent signal localized to basal epithelial 
cells and in heavily keratinized filiform papillae.90 These results suggest that gonadal 
hormones are necessary for maintaining tongue epithelium thickness and that 
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artemin is important in keratinization. Further, artemin overexpression indicates 
overall atrophy of the lingual nerve, as compared with wild-type animals.89,90 
Interestingly, this atrophy was mainly observed in thinner fibers, and particularly in 
unmyelinated fibers, which corresponds to findings from BMS patients.23,37,28 These 
animals showed hyper-innervation of artemin receptor (GFRα3)-positive fibers (some 
of which contained TRPV1) in the epithelial layer, and fungiform papillae. The 
densities of these fibers were much higher in transgenic mice that overexpress 
artemin than in wild-type mice,90 and in rats treated with the artemin inducer 
2,4,6-trinitrobenzenesulfonicacid (TNBS) than in vehicle-treated rats.89 These 
findings resemble those seen in BMS patients, namely, elevated TRPV1 expression 
in atrophied small-nerve fibers.40  
Many BMS patients complain of xerostomia, the subjective sensation of dry 
mouth.13,91–94 Xerostomia is usually associated with decreased salivary flow rate,95 
although it is not always caused by hyposalivation.96 It is generally accepted that 
hyposalivation leads to various oral complaints97 and aggravates oral burning 
symptoms. Mental stress98–100 and menopause101,102 suppress salivary secretion, 
especially unstimulated flow rate. Some studies indicated that unstimulated salivary 
flow rate was significantly lower in BMS patients than in controls, despite the absence 
of a significant difference in stimulated flow rate.103,104 Minor salivary glands are 
important in oral tissue lubrication,105 and oral dryness in resting state is considerable 
because of decreased secretion by minor salivary glands.106 Minor salivary glands 
may be more easily affected by denervation of the chorda tympani nerve because 
they are located in the lamina propria and purely parasympathetically innervated. 
Latent oral dryness keeps the oral mucous intact but may result in latent inflammation 
and subclinical changes in the tongue. Nakaya et al. reported that experimentally 
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drying the tongue increased nocifensive behavior against mechanical stimuli in rats 
without any inflammatory changes in the tongue epithelium and increased 
phosphorylation of extracellular signal-regulated kinase (ERK), a MAP kinase in 
trigeminal spinal subnucleus caudalis neurons, after noxious stimulation of the 
tongue.107 Agha-Hosseini et al. reported that the severity of dry mouth was inversely 
correlated with whole salivary 17β-estradiol concentration108 and positively correlated 
with whole salivary cortisol concentration.109 Some studies reported elevation of 
levels of pro-inflammatory cytokines in saliva including IL-2,33 IL-6 33,110,111 and 
TNF-111 and decrease in the level of anti-inflammatory cytokine IL-10 110 in BMS 
patients when compared to controls. Authors have suggested that preclinical level of 
inflammation may be involved in the pathogenesis of BMS,33 although other studies 
have described no significant changes of these cytokine levels in saliva.112–114 Taken 
together, it is hypothesized that the lack of neuroprotective steroids leads to 
hypofunction of minor salivary glands that contributes in inducing oral dryness and 
preclinical inflammation of oral mucosa, and these peripheral changes may be 
involved in generating burning mouth symptoms. 
Sex hormones are synthesized in gonadal organs and in the central and 
peripheral nervous systems.115,116 In neural cells, these steroids are synthesized from 
cholesterol in the mitochondria and modulate transcription of DNA and subsequent 
protein synthesis in the nucleus.117 These steroids are neuroprotective and are 
deeply involved in the synthesis of neurotransmitters that generate pain-related 
behaviors.116 They modulate the function of various neurotransmitter receptors and 
exert neuroprotective effects.118 Progesterone mediated a significantly better 
recovery from mechanical allodynia as compared with vehicle-treated rats when 
administered immediately after neuropathic surgery to the sciatic nerve.119 GDNF and 
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its family modulate the effect of neuroprotective steroids.120 Shinoda et al. noted 
increased mRNA expression of artemin in the epithelium of the tongue surface in 
BMS patients.89 Further, they reported that induction of artemin in the rat tongue 
epithelium induced pain-related behavior to heat pain and increased TRPV1-positive 
afferents in tongue epithelium.89 Boucher et al. reported that oral pain–related 
behavior was induced by ovariectomy but not by chorda tympani nerve transection in 
rats.121 They also observed c-fos–like immunoreactivity both in the trigeminal 
subnucleus caudalis neurons and in neurons in the rostral NTS. This expression was 
significantly stronger in ovariectomized rats.121 These results show that the deficit of 
gonadal steroids, namely neuroprotective steroids, directly or indirectly generates 
pain-related behaviors through the peripheral and the central mechanisms. 
There is increasing evidence, including the findings of brain imaging studies, 
to explain the behavioral findings observed in neurophysiological and 
electrophysiological studies of BMS patients. fMRI studies revealed that noxious heat 
stimulation applied at the perioral region evoked greater activity in the anterior 
cingulate, motor, prefrontal, and insula cortices in BMS patients than in controls,122,123 
although perceived painful sensation was similar in BMS patients and controls. 
Further, ongoing noxious heat stimulation at the lower lip induced temporal 
summation of the brain activity in these areas in BMS patients.124 Contrarily, it is 
reported that repetition of noxious stimulation with an appropriate interval induces 
pain habituation in healthy persons,125,126 which is likely caused by C-fiber 
fatigue.127,128 In our study, repeated thermal stimulation of the lower lip resulted in 
temporal suppression of brain activity, mainly in the cingulate cortices, without 
showing perceived pain habituation in BMS patients as compared with controls.123 
Thus, BMS brain more easily shows temporal summation to ongoing painful 
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stimulation and lack of pain inhibition against repeated noxious stimuli when 
compared with controls. These abnormal responses in brain areas associated with 
pain modulation may explain the findings of previous studies that BMS patients 
complained of reduction of pain tolerance34,80,129 without showing reduction of pain 
threshold.34,80,130 Voxel-based morphometry studies showed significant changes in 
grey matter volume in the medial prefrontal cortex,131,132 hippocampus,131 anterior 
and posterior cingulate cortices,132 motor cortex,132 and insula/frontal operculum.132 
Wada et al. studied the macroscopic fiber pathway of 83 brain regions from 60-axis 
diffusion tensor data by using 83 × 83 probability tractography and reported that the 
bilateral rostral anterior cingulate cortex, right medial orbitofrontal cortex, and left pars 
orbitalis had significant roles in local network metrics in the BMS brain.133 Analysis of 
the BMS brain network showed that the anterior cingulate cortex and medial/orbital 
area of the prefrontal cortex had strong connectivity with the medial ascending pain 
pathway.133 Further, Khan et al. reported significantly stronger connectivity between 
the medial prefrontal cortex and hippocampus in the afternoon than in the morning, 
and this difference was positively correlated with the degree of anxiety and 
depression.134 As we learned before, denervation of the chorda tympani nerve leads 
to predominance of trigeminal inputs in the oral mucous membrane. Then a portion of 
nociceptive inputs via trigeminal afferents reach the NTS and lack of gustatory control 
again disinhibits trigeminal impulses here. Potentiated nociceptive signals ascend to 
the amygdala via the PBN and activate the medial pain system.61,65,135  Jaaskelainen 
and colleagues hypothesized that impairment of the striatal dopamine loop may 
create a deficiency in inhibitory pain modulation in persons with chronic neuropathic 
orofacial pain.136 The limited number of neurotransmitter positron emission 
tomography studies reported that fluorodopa uptake in the striatum was lower in BMS 
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patients than in controls.38,39,137 These studies revealed a decline in striatal 
endogenous dopamine levels in BMS patients and a resulting defect in 
dopamine-mediated top-down pain modulation. Hagenberg et al. reported a decrease 
in D2 receptor coupling, which led to a decrease in D1/D2 ratio in the striatum of BMS 
patients.39 Clinical reports support this intracranial dopaminergic dysregulation, and 
some researchers reported comorbidity with Parkinson disease138–141 and, more 
recently, with restless legs syndrome (RLS).138,142–146 In addition, some studies 
reported that the D2 agonist pramipexole alleviated burning mouth symptoms.144,147 
Some researchers have hypothesized that there is an overlap in the diagnoses of 
BMS and RLS.142,143,147 In healthy persons, the motor cortex sends impulses to the 
striatum and receives feedback from the thalamus.148 In RLS, the motor cortex is 
hyperexcitable,149 as it is in BMS patients.122,123 Nigrostriatal dopaminergic fibers 
have a crucial role in the onset of Parkinson disease and RLS.137 Some of these 
fibers contain somatosensory fibers, and lesions in this pathway reveal 
deafferentation, which induces trigeminal pain.150,151 In summary, BMS patients may 
perceive burning pain largely by central mechanisms based on the impaired pain 
modulation. Dysregulation of dopaminergic system at the basal ganglia may be 
involved in top-down control 136 from the motor cortex. Imaging studies of BMS 
patients show that the function of the brain areas that form the salience network is 
impaired.152 These experimental findings indicate that the pain modulation system 
(motor cortex–basal ganglia–thalamus, anterior cingulate cortex–prefrontal 
cortex–insula cortex–hippocampus) is overused, even in the resting state, and easily 
overwhelmed in the BMS brain. 
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3) Psychological component 
Researchers who studied character profiles of BMS patients have reported a high 
tendency towards neuroticism as shown in previous reports and these patients might 
have a personality trait making them cautious in starting new things.153 They have 
suggested some personality traits are associated with depression.153 Recent 
systematic review has reported the importance of anxiety and depression in 
comorbidity with BMS, although it did not found any differences in roles of these 
mood disorders from that in other chronic pain conditions.18  To investigate the 
psychological involvement in BMS, we have to learn mood change after menopause 
and in the chronic pain conditions, first. It is well known that dysregulation of sex 
hormones―neuroprotective steroids leads to psychological distress.154,155 
Neuroprotective steroids, especially progesterone metabolites, modulate 
gamma-aminobutyric acid (GABA)A receptors.
156 Substantial evidence suggests that 
some neuroprotective steroids are associated with mood disorders via GABAA 
receptors.157 Allopregnanolone exerts an anxiolytic effect by inducing positive 
allosteric modulation of the GABAA receptor and negative modulation of 
hypothalamic-pituitary-adrenal (HPA) axis activity.155 Estradiol facilitates serotonergic 
neurotransmission in brain areas associated with affect and inhibits monoamine 
oxidases in ovariectomized animals.158 Progesterone and estrogen regulate the 
endogenous anxiolytic effects of serotonin and allopregnanolone.155 
Allopregnanolone synthesis in the brain was affected by social isolation only when 
female mice had undergone ovariectomy,159 which indicates that circulating gonadal 
steroids have a role in the biosyntheses of neuroprotective steroids in the brain. 
Therefore, after menopause the risks of anxiety and depression increase because of 
reduced serotonergic neurotransmission, reduced GABAergic inhibition and less 
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efficient HPA axis activity.155 Furthermore, mental stress induces downregulation of 
the hypothalamic-pituitary-gonadal (HPG) and HPA axes by modulating the GABAA 
receptor,160 thereby reducing sex hormone levels.161 This modulation of the HPG axis 
is exerted by tonic GABAergic inhibition of gonadotropin-releasing hormone via 
extrasynaptic δ subunits.160 In chronic mentally stress, especially post-traumatic 
stress disorder, the GABAA receptor configuration changes. Expressions of the α4, α5, 
and δ subunits significantly increase, and α1 and α2 subunit expression markedly 
decreases.162 The α4, α5, and δ subunits are highly sensitive to neuroprotective 
steroids.162 In women with BMS, there may be a decrease of neuroprotective steroids 
after menopause, and lack of neuroprotective steroid coupling to these subunits may 
lead to a lack of chloride influx that mediates GABAergic inhibition. Interestingly, 
benzodiazepines have been long used to treat mood disorders; the anxiolytic and 
sedative actions result from binding of α1 and α2 subunits,163 whereas α4, α5 
subunits have low sensitivity to benzodiazepines.162 Two studies reported insufficient 
effectiveness of benzodiazepines, including clonazepam, for chronic anxiety in 
persons with BMS.82,164 Gremeau-Richard et al. in a post-hoc analysis classified BMS 
in relation to response to topical clonazepam and lingual nerve block as peripherally 
affected cases (representing involvement of peripheral GABAA receptors), centrally 
affected cases (representing an unknown central mechanism), and combined 
peripherally and centrally affected cases. In the centrally affected group, anxiety and 
depression were more frequently observed,82,165 which suggests that the insufficient 
effectiveness of clonazepam was due to lack of coupling to its receptors in the 
periphery and brain. Grushka et al.166 reported that the longer patients had BMS, the 
less effective clonazepam was in alleviating pain, which might reflect changes in 
GABAA receptor configuration. It is known that reduced synthesis of allopregnanolone 
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in the hippocampus, amygdala and medial prefrontal cortex results in depression167 
and anxiety168 and these brain areas are reported to indicate altered brain 
connectivity in BMS patients.133,134In summary, these findings suggest the role of 
neuroprotective steroids on mood in BMS patients and their effect on GABAA 
receptors. Figure 1 summarizes the possible pathophysiological mechanisms 
underlying BMS. 
 
2. Management perspectives 
The natural course and remission rate of BMS are unclear. Spontaneous remission 
within 5 years of onset was reported in only 3% of patients.169 Longitudinal follow-up 
studies of BMS patients are expected to answer questions regarding specific 
temporal changes in manifestations and clarify the time course and prognosis of BMS. 
The etiology of BMS is not known and no curative treatment has been reported. 
Treatments found to be beneficial in meta-analyses include topical and systemic 
clonazepam170,171 and cognitive behavioral therapy.172 The details of these treatments 
have been reported elsewhere,173,174 and this review article will discuss treatment 
options from an etiological perspective.  
 Peri- and postmenopausal women are predisposed to BMS;25–27 thus, some 
clinicians recommend hormone replacement therapy (HRT) to such patients.102,175 As 
described above, sex hormones are likely involved in the etiology of BMS; therefore, 
HRT could be the best treatment to address the cause of BMS. Unfortunately, few 
studies have investigated HRT for BMS. Using conjugated estrogens plus additional 
application of medroxyprogesterone acetate, Forabosco et al. examined the effect of 
HRT on oral symptoms.175 Although the details of the treatment protocol were not 
described, HRT relieved xerostomia, burning discomfort and dysgeusia. In addition, 
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the authors used exfoliative cytology to study the ratio of collected cells originating 
from various layers of the oral mucous epithelium and reported that HRT increased 
the thickness of mature mucosal epithelium.175 A cross-sectional study of the effect of 
HRT on oral symptoms found that oral pain and dry mouth were significantly less 
prevalent in patients receiving HRT than in those not receiving HRT.92 The findings of 
these studies suggest that HRT is effective. However, HRT may increase the risk of 
thrombogenicity, and expert recommendations exclude elderly patients and those 
with a history of diabetes, coronary artery disease, stroke, or long-term menopause 
from the indications for HRT.176 Another concern is that the effectiveness of HRT is 
not dose dependent. In an animal model, Li et al. reported that the number of vaginal 
nerve fibers was lower after ovariectomy and that estrogen replacement therapy 
restored fiber density; however, the treatment effect was not dose dependent.84 
Studies of the effects of neuroprotective steroids on nocifensive behaviors of animals 
after nerve injury showed significant recovery from neuropathic pain.116,177–179 
However, animals that received progesterone at a different schedule and duration 
showed no or insufficient recovery from neuropathic pain.119 These findings from 
animal studies suggest that any management protocol involving gonadal steroids will 
not be straightforward. Although HRT appears promising, it may present safety 
concerns for subgroups such as elderly patients and women with a long menopause, 
both of which have an increased risk of BMS. These challenges complicate HRT for 
BMS patients.  
 
From an endocrinological perspective, translocator protein 18KDa (TSPO) 
ligands are another candidate in BMS treatment. TSPO translocates cholesterol into 
mitochondria and exerts neurosteroidergic effects by synthesizing neuroprotective 
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steroids.162 The TSPO ligand etifoxine is now used clinically to treat anxiety180 and 
has been reported to reduce neuropathic pain.181–183 
 BMS has historically been regarded as a stress-related—a so-called 
psychogenic or functional—pain condition.15–18,24 However, to our surprise few 
randomized controlled trials (RCTs) have examined the effect of antidepressants and 
anxiolytics other than clonazepam on BMS symptoms.171 Fluoxetine was not superior 
to placebo in the management of pain and depression symptoms,184 while trazodone 
showed moderate effectiveness.185 Although some evidence from open-label studies 
supports the effectiveness of commonly used antidepressants for pain remission in 
BMS patients,77,186–190 further study is required for a definitive conclusion. These 
drugs do not necessarily exert pain-relieving effects through their psychogenic 
mechanisms in chronic pain conditions. As mentioned above, SSRIs and SNRIs have 
neurosteroidergic effects at low, non-serotonergic, doses in the brain162 and facilitate 
biosynthesis of neurosteroids.191 These drugs are expected to be further investigated 
in controlled studies. Thus, current use of these drugs is primarily based on anecdotal 
clinical experience and is not supported by unambiguous evidence.192 Clonazepam 
has been administered as a systemic,193 topical,165,194,195 and combined 
systemic/topical agent.196 Topical clonazepam is a hypothesized etiology-based 
modality and has limited side effects.165 This systemic and topical effect of 
clonazepam is believed to be exerted through its agonistic action on GABAA 
receptors.165,171,197 There are a couple of studies that topical application of GABA 
analogs reduces experimental burning pain.198,199 However, as described above, 
changes in the extrasynaptic GABAA receptor configuration have been noted, 
specifically downregulation of the α2 subunit (that is sensitive to benzodiazepines), 
and upregulation of the α4 and α5 subunits (that are insensitive to 
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benzodiazepines),162 which complicates the working mechanism of clonazepam in 
BMS patients. Although a meta-analysis of clonazepam revealed good pain relief in 
BMS patients, only two of the included studies excluded secondary BMS.171 Further 
RCT studies of the effects of clonazepam should include patients with strictly 
diagnosed primary BMS.  
A recent network meta-analysis of pharmacological management of BMS 
pain indicated that capsaicin had beneficial effects.200 Topical capsaicin is indeed an 
etiological treatment option.201,202 As described above, in the epithelium of BMS 
patients, TRPV1 channels are overexpressed in remaining fibers after denervation of 
thin fibers.40,58 Capsaicin induces depletion of substance P- and Ca2+-dependent 
desensitization of TRPV1 channels, which leads to analgesia.203 A double-blind 
crossover study revealed that a 0.025% capsaicin oral rinse significantly reduced 
pain.202 When applied topically, capsaicin is generally safe.204 However, topical 
application of capsaicin in the oral cavity often leads to intolerable adverse effects, 
including gastric pain, dysgeusia and severe burning pain in the oral mucosa.202 
Capsaicin has gastroprotective effects;205 thus, gastric pain may be a sign of 
hypersensitivity to capsaicin. Capsaicin-induced analgesia requires activation of 
TRPV1 channels, which results in an extreme burning sensation and dysgeusia.60,202 
Further, some patients were reported to experience persistent burning pain even after 
repeated application of capsaicin.202 This persistent burning sensation after capsaicin 
application is likely attributable to the fact that, even after desensitization, TRPV1 
channels have further activation capacity.203 These characteristic features of 
capsaicin must be further studied before topical capsaicin can be regarded as a first 
line-treatment for BMS. 
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 Patients with Parkinson disease complain of persistent pain,206 and BMS 
prevalence is high among this patient group.140 Dopamine is deeply involved in pain 
modulation, although it has been suggested that pain in Parkinson disease was 
mainly due to muscular and structural abnormalities.207 Some reports as mentioned 
previously suggest a dopaminergic mechanism in BMS etiology,38,39,137,207–209 and 
converging evidence shows that neuroprotective steroids are involved in 
dopaminergic pain modulation.210,211 A case series including five BMS patients with 
restless leg syndrome reported successful pain relief by L-Dopa.143 The D2 agonist 
pramipexol relieved BMS symptoms.144 These findings suggest that dopamine 
agonists have potential in BMS management. However, reports on the effects of 
L-Dopa are conflicting. One patient complained of burning mouth symptoms after 
taking daily L-Dopa, which completely disappeared after cessation of the drug.139 
Olanzapine, a dopamine blocker, alleviated BMS symptoms in two patients.189 
Because of the potential adverse effects of these drugs, including tardive dystonia,212 
they should be prescribed with caution.  
Interventions that facilitate inhibitory pain pathways are now being utilized. 
Brain stimulation is applied by using two modalities: repetitive transcranial magnetic 
stimulation (rTMS)213–215 and transcranial direct current stimulation (tDCS).216 rTMS 
targets the primary motor cortex (M1),215 secondary somatosensory cortex (S2),215 
and dorsolateral prefrontal cortex (dlPFC).217 The mechanism of pain reduction is 
believed to be mediated by direct or indirect activation of functional connectivity 
between PFC and the limbic system,215 which is involved in pain inhibition and 
emotional function (mood and affect).134 tDCS has recently been used to manage 
orofacial pain, but its therapeutic effectiveness for chronic temporomandibular 
disorders is unclear.218,219 These modalities are new, and well-designed RCTs are 
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needed in order to determine their effectiveness. Cognitive behavioral therapy (CBT) 
has also been used220 and facilitated the pain modulation system of the brain in 
chronic pain patients.221,222 CBT can be used with or without medication, as it has few 
serious complications.223  
 
Conclusions 
BMS is characterized by burning pain sensation, dysgeusia, xerostomia, and 
psychosocial distress. All these manifestations may be associated with menopause, 
which leads to neuroprotective steroid deficiency and subsequent atrophy of 
small-nerve fibers in the oral mucous membrane and central nervous system 
dysfunction resulting in alterations to the brain network. Therefore, modulation of pain 
and mood is impaired in the brain. These findings suggest that BMS could be a 
neuropathic condition; however, our hypothesis suggests that there may be atrophy of 
the gustatory and parasympathetic nerve fibers but not to the somatosensory nerve 
fibers, which may induce alteration in pain tolerance but not in pain threshold. Thus, 
the mechanism of neuropathic pain in BMS may not be due to the direct damage to 
the somatosensory nervous system but may be due to the dysfunction in the 
somatosensory nervous system and the brain network.  
One of the most critical but postponed problems is that the prevalence of 
BMS is 0.7–3.7% in the adult population.224 Because all mature women experience 
menopause, the cause of BMS cannot be fully explained by hormone dysregulation; 
something else must trigger BMS symptoms. In addition, we need further data on 
neuroprotective steroids, which are the target of current research.  
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Figure Legends 
Fig. 1 Putative pathophysiology of BMS 
Menopause induces decreases in gonadal and adrenal steroids. A deficit of 
neuroprotective steroids following gonadal hypofunction is believed to induce atrophic 
changes in thin fibers in the epithelial layer of the oral mucosa. The atrophied fibers 
that innervate taste buds are mainly chorda tympani nerve fibers with P2X2 and P2X3 
receptors and conduct taste information. In contrast, the remaining fibers in the 
subepithelial layer are trigeminal nerve fibers with rich TRPV1 channels. This 
“alternative” innervation results in the predominance of the trigeminal nerve and 
acceleration of TRPV1 channel function, which induce dysgeusia and hypersensitivity 
to capsaicin and hot foods. However, somatosensory fibers are not damaged, and 
quantitative sensory testing shows no significant changes in somatosensory and pain 
detection thresholds. Decreased inputs from chorda tympani nerve fibers lead to 
disinhibition of trigeminal impulses at the NTS and alter the mutual sensory control 
between the trigeminal, the chorda tympani and the glossopharyngeal nerves. Lack of 
neuroprotective steroids leads to mood changes by inhibiting serotonin synthesis and 
GABAergic modulation. Chronic mental distress induces changes in GABAA receptor 
configuration that reveals a decrease in α1, α2, and δ2 subunit expression, which are 
the target of benzodiazepines. Contrarily, expressions of the α4, α5, and δ subunits 
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that have a high sensitivity to neuroprotective steroids but almost no sensitivity to 
benzodiazepines increase. These changes may be involved in psychological distress 
and in generating burning pain. This mental distress and persistent pain suppress the 
function of the pain modulation system of the BMS brain. Furthermore, dysregulation 
of the dopaminergic system in the basal ganglia may be involved in disordered 
top-down pain modulation.  
 
 
 
